期刊
MOLECULES
卷 26, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/molecules26102943
关键词
antibody– drug conjugate; ADC; monoclonal antibody; linker; cytotoxic payload; tutorial review
资金
- Transcriptogen Limited within the Rahman laboratory
ADCs are a family of targeted therapeutic agents for cancer treatment, with over 80 currently in clinical development and 11 approved by the FDA. They offer enhanced targeting of cancer cells and reduced toxic side effects compared to traditional approaches, making them an attractive prospect in oncology research.
Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small-molecule payloads and two with biological toxins) approved for use by the FDA. Compared to traditional small-molecule approaches, ADCs offer enhanced targeting of cancer cells along with reduced toxic side effects, making them an attractive prospect in the field of oncology. To this end, this tutorial review aims to serve as a reference material for ADCs and give readers a comprehensive understanding of ADCs; it explores and explains each ADC component (monoclonal antibody, linker moiety and cytotoxic payload) individually, highlights several EMA- and FDA-approved ADCs by way of case studies and offers a brief future perspective on the field of ADC research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据